

Prestige Biopharma's new vaccine manufacturing center for infectious disease including COVID-19

With an estimate capacity to produce 100,000 liters, the center is scheduled to be completed by the end of 2021 in Prestige Biologics' second manufacturing site (Campus 2).

Prestige Biopharma Ltd. (PBP), specializing in the development of antibody therapeutics, announced that the company will be rolling out a vaccine manufacturing center.

PBP made this announcement on the 8th March 2021, that it is on target to build a global scale vaccine manufacturing center with a total area of approximately 8,500 square meters by the end of the year and will be utilizing a part of Prestige Biologics' Campus 2 site (2,000 square meters). This center will be built independently apart from the other projects of Prestige Biologics.

With a global-scale production capacity to produce 100,000 liters, the center will be able to meet the demands of vaccines for any infectious disease and not just limited to COVID-19.

PBP's vaccine manufacturing center will be designed to be applied to various manufacturing process and maximize efficiency utilizing Prestige Biologics' customized engineering technology. The company is slated to begin the construction this month and to complete the project by the end of the year and will be including a production system validation.

PBP CEO, Dr Lisa S. Park commented, "the prolonged fight against the COVID-19 pandemic has created both expectations for the related vaccines and growing concerns for the possible infectious viral disease at the same time" and "hopefully this global-scale vaccine manufacturing center will contribute to generating the company's new revenue sources and at the same time to assist in defeating the pandemic as well".